SCHEMBL5863642

SCHEMBL5863642

CCNC(=O)C1(CCCN2CCN(c3ccc4c(c3)C(=O)N(Cc3cccc(C)c3)C4)CC2)c2ccccc2Sc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.42
TP53 P04637 2/20 0.42
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
ACACB O00763 1/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
IDE P14735 1/20 0.37
HTT P42858 1/20 0.37
DRD2 P14416 5/20 0.37
DRD3 P35462 5/20 0.37
DRD5 P21918 3/20 0.37
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
NPBWR1 P48145 1/20 0.36
MCHR1 Q99705 1/20 0.36
HTR1A P08908 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863263 0.98 LMNA (0.43) LMNAKMT2ATP53NPSR1KDM4E
SCHEMBL5863395 0.94 LMNA (0.43) LMNAKMT2ATP53NPSR1KDM4E
SCHEMBL5863614 0.94 DRD2 (0.41) KMT2ATP53KDM4EALDH1A1ACACB
SCHEMBL5863677 0.93 LMNA (0.45) LMNAKMT2ATP53KDM4EALDH1A1
SCHEMBL5864030 0.92 HTR7 (0.42) LMNAKMT2ATP53KDM4EMEN1
SCHEMBL5863660 0.92 ATM (0.41) LMNAKMT2ATP53KDM4EALDH1A1
SCHEMBL5863803 0.92 LMNA (0.43) LMNAKMT2ATP53NPSR1KDM4E
SCHEMBL5863749 0.92 LMNA (0.42) LMNAKMT2ATP53NPSR1KDM4E
SCHEMBL5863241 0.91 DRD2 (0.42) KDM4EALDH1A1ACACBMAPTDRD2
SCHEMBL5864256 0.91 DRD3 (0.43) DRD2DRD3HTR1AKCNH2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC LMNA 508/4885KMT2A 2580/4885TP53 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.